LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
Journal
Journal of Thoracic Oncology
Journal Volume
11
Journal Issue
4
Date Issued
2016
Author(s)
SDGs
Other Subjects
epidermal growth factor receptor; osimertinib; advanced cancer; adverse event; adverse outcome; Article; Asian; cohort analysis; controlled clinical trial; controlled study; diarrhea; drug dose reduction; drug efficacy; drug safety; EGFR gene; exon; female; follow up; gene deletion; gene mutation; human; major clinical study; male; mutational analysis; non small cell lung cancer; outcome assessment; overall survival; paronychia; phase 1 clinical trial; priority journal; progression free survival; stomatitis; treatment duration; treatment response
Publisher
Elsevier Inc
Type
journal article